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Introduction 
The incidence of inflammatory bowel disease (IBD) is increasing and the onset of Crohn’s 
disease (CD) and ulcerative colitis (UC) often coincide with the peak childbearing years. In 
North America, the prevalence of UC is 249 per 100,000 persons and the prevalence of CD is 
319 per 100,000 persons; in Europe, prevalence of UC and CD has been reported to be as high as 
505 per 100,000 persons and 322 per 100,000 persons, respectively [1]. Nørgård et. al. showed 
that mean incidence rates in Denmark, were highest among women ages 15-29 [2].  While 
research regarding fertility, medication safety during pregnancy, and pregnancy outcomes is 
increasing, there are still many knowledge gaps in these areas. Management of IBD is growing 
more complex and the stakes are especially high when dealing with a pregnant patient.  For 
example, there are now seven different biologic therapies in use for IBD and they are not 
infrequently continued during conception and pregnancy. Many young patients who are 
contemplating or who have had surgery for IBD, especially an ileoanal pouch anastomosis 
(IPAA) or an ostomy, do not want to give up the opportunity to have children. When 
contemplating medical or surgical therapy, the most urgent questions patients often have are 
those regarding fertility and safety of a future pregnancy. Since this is a complex area with many 
knowledge gaps, the best way to manage women with IBD who are pregnant or contemplating 
pregnancy is a multidisciplinary approach. Team members often include a high-risk obstetrician, 
especially for women on immunosuppressive medications, with severe and/or active disease or 
with a history of IBD surgery, an infertility specialist who can advise on assisted reproduction if 
needed, and a colorectal surgeon for patients with a history of IBD surgery or perianal fistulizing 
disease, in addition to the patient’s gastroenterologist. A pediatrician with experience in caring 
for children of mothers with IBD should also be part of the multidisciplinary team. By 
integrating expertise from these disciplines, women with even very complex IBD should be able 
to have a healthy pregnancy and delivery. This article will review the recent literature on the 
effects of fertility and pregnancy on IBD, the management of disease exacerbation during 
pregnancy and also discuss questions that remain unanswered regarding fertility and pregnancy 
in IBD. 
 
Fertility: Are fertility rates decreased among women with IBD? 
Fertility, or the ability to produce offspring, is often a concern among women with a diagnosis of 
IBD, and may affect decisions regarding medical management at the time a woman is trying to 
conceive. Fertility is not affected by IBD in general, although pelvic surgery may affect the 
ability to conceive [3]. It is not known whether disease activity can affect the ability to conceive. 
Studies have shown that there are no differences in fertility rates among women with and without 
IBD [4, 5]. Despite the lack of difference in fertility rates, women with IBD tend to have fewer 
children, a concept known as “voluntary childlessness.” Tavernier et. al. showed that women 
diagnosed with CD have half as many children as women without IBD [5]. Women with IBD 
often choose to have fewer children for a number of reasons, including fear of worsening disease 
during pregnancy, concern for passing IBD on to their offspring, concern of disease recurrence 
because of pregnancy, concern regarding increased stress due to a child and fear of not being 
able to care for a child [4, 6].  
 
While it was previously shown that there was no decreased fertility rate among women with IBD 
[7], the recent consensus statement published by the European Crohn’s and Colitis Organization 
(ECCO) states that although there is no evidence that UC or inactive CD disease has an impact 
on fertility, fertility may be reduced in active CD [8]. This statement is further supported by 
recent studies showing decreased levels of anti- Müllerian hormone (AMH) in women with 
active CD [9]. In addition, ECCO hypothesizes that inflammation in the fallopian tubes and 
ovaries and tubal adhesions associated with prior surgical interventions may impact fertility [8].  
 
Accurate assessment of fertility can be difficult, especially if there is increased voluntary 
childlessness among women with IBD. AMH levels have recently been shown to be a good 
indicator of ovarian reserve and as a marker of fertility among women of reproductive age [9].  
One study of 35 women with CD and 35 controls without CD showed significantly lower levels 
of serum AMH in the CD population [9]. Interestingly, among this same population, serum 
AMH levels were significantly lower among women with active CD than among those in 
remission, and a trend was seen showing lower serum AMH levels among women who had 
disease duration of CD for at least 5 years but this difference was not statistically significant [9]. 
This study raises the question of the effect of disease severity on fertility and also the long-term 
effects of CD on fertility.  
 
Fertility rates among women who have undergone surgery for IBD have been shown to differ 
from rates of women who have not had surgical intervention. Specifically, a history of IPAA is 
associated with a 2-3 fold increased risk of infertility [3, 10, 11]. One meta-analysis showed a 
three-fold increased risk of infertility after IPAA, with infertility rates ranging from 14.6% 
among women before surgery to 48% among women after IPAA [3]. Another meta-analysis 
showed increased infertility rates from 12% to 26% before and after restorative proctocolectomy 
among women with UC [10]. A retrospective study of fertility rates among women who had 
undergone proctocolectomy and ileostomy for UC and CD reported a reduction in fertility to 
37% from 72% after surgery [12]. Similarly, 17 percent of patients with familial adenomatous 
polyposis who underwent either ileorectal anastomosis, IPAA, and proctocolectomy 
with ileostomy reported difficulties with fertility after surgery, though type of surgery was not 
associated with fertility outcomes [13]. Women with UC who have undergone IPAA have been 
shown to have abnormal hysterosalpingography; a small study of 21 patients showed bilateral 
occlusion of the fallopian tubes in 2 of 21 patients after IPAA and unilateral occlusion in 9 [14]. 
Only 7 of the 21 women evaluated had a normal hysterosalpingography after IPAA [14].  
 
Recent studies evaluating the effect of laparoscopic IPAA have shown lower rates of infertility 
after laparoscopic IPAA compared to open surgery, and Beyer-Berjot et. al. showed no 
difference in fertility rates among women who underwent surgery for laparoscopic IPAA and 
laparoscopic appendectomy, a procedure that has not been associated with decreased fertility 
[15]. Similarly, Bartels et. al. showed higher pregnancy rates among women who had undergone 
laparoscopic IPAA compared to those who had open procedures [16]. One study showed that 
women with UC who have undergone IPAA, however, have similar success with pregnancy via 
in vitro fertilization (IVF) as women with UC without IPAA and women without IBD [17]. 
Although the cohort of women with UC who had undergone IPAA only included 22 women, the 
study suggests that among this population, conception via IVF likely is not impacted by prior 
surgical procedures. In addition, irrespective of medical or surgical treatment, initial research 
shows that IVF is just as successful among women with CD and UC as in women in the general 
infertile population [18]. This recent retrospective matched cohort study indicated that women 
with IBD who undergo IVF achieve rates of live births comparable to those of infertile women 
without IBD who undergo IVF [18] though additional studies are warranted to confirm these 
results.  
 
Fertility knowledge gaps: 
While it has not been shown that a diagnosis of IBD is associated with decreased fertility, data 
suggest that certain factors, such as surgical history, disease severity and duration of disease, 
may affect a woman’s ability to conceive naturally. Further studies are necessary to clarify the 
effects of surgical intervention, differences in laparoscopic versus open operations, and their 
effect on fertility as well as the possible impact of disease severity on fertility. In addition, 
further research is needed regarding on the role of AMH hormone and whether this can be used 
to predict which women to refer to a fertility specialist before 12 months of unsuccessful 
pregnancy. Due to the nature of studies using large databases or population-based studies, it is 
difficult to calculate the rate of pregnancy loss in women with IBD and to estimate the rate of 
ectopic pregnancy and whether it is increased from that in the general population. At this time, 
we recommend that post-surgical patients either with irregular menstrual cycles or with more 
than 3 months without success of conception should be referred to a fertility specialist. Data 
suggest that laparoscopic surgery may be associated with lower rates of infertility, and the 
success of IVF in the IBD population is promising.  
 
Pregnancy: 
What are the effects of pregnancy on IBD and the effects of IBD on birth outcomes?  
The majority of pregnant women with IBD will experience normal pregnancies; a meta-analysis 
from 1986 following over 1300 women with UC and 700 women with CD showed that 83-85% 
of women with IBD had normal pregnancies [19]. The status of disease at the time of conception 
can often help predict the course of disease activity during pregnancy. A woman who has active 
disease at the time of conception is more likely to have active disease throughout pregnancy than 
a woman who is in remission at the time of conception. A meta-analysis evaluating disease 
activity during pregnancy in relation to disease activity at conception showed that among women 
with UC, patients had a higher risk of active disease during pregnancy if they entered pregnancy 
with active disease [20]. Similar results were seen among women with CD [20]. The 
recommendation for women to be in remission at the time of conception is further supported by a 
recent retrospective study showing active disease at the time of conception is associated with 
increased adverse pregnancy outcomes among women with IBD [21]. One study has shown that 
disease activity probably has an impact on preterm birth, emphasizing the importance of disease 
management throughout pregnancy [22].  
 
It has not been shown that pregnancy itself can predispose a woman to a flare of IBD. Pedersen 
et. al. followed pregnant and non-pregnant women with IBD and found no statistically 
significant difference in the disease course between these two groups [23]. However, it has been 
suggested that IBD can affect birth outcomes. A recent meta-analysis showed increased odds of 
preterm birth (1.85; 95% CI 1.67-2.05), small for gestational age birth weight (1.36; 1.16-1.60), 
congenital anomalies (1.29; 1.05-1.58) and stillbirth  (1.57; 1.03-2.38) for women with IBD 
compared to non-diseased controls [24]. Twenty-three studies including over 15,000 women 
with IBD were included in this meta-analysis, but the specific effects of flare on these birth 
outcomes are unknown. Boyd  et. al. showed that women with IBD using systemic 
corticosteroids are at increased risk of severe pre-eclampsia, preterm premature rupture of 
membranes and medically induced preterm delivery (HR all >7), suggesting that either disease 
severity and/or the use of these medications may affect these outcomes [25]. There was also a 
modest increase in congenital abnormalities in women with Crohn’s disease only (RR 1.85; 95% 
CI 1.06-3.21). There was no evidence of an association between IBD and pregnancy loss. 
Additional studies have also shown increased rates of preterm delivery, small for gestational age, 
admission to the neonatal intensive care unit (NICU) and low 5-minute APGAR score [21].   
 
Knowledge gaps: 
There are currently many knowledge gaps regarding the effects of pregnancy on IBD making it 
difficult to advise women with IBD about pregnancy. In addition, we know that women with 
IBD have an increased risk of adverse birth outcomes, but there are insufficient data to be able to 
identify which women are more likely to have adverse outcomes. Data show that women who 
enter pregnancy in remission are less likely to have active disease during pregnancy than women 
who conceive during a flare; however, there are currently no data about how long a woman 
should be in remission before trying to conceive. There are also no data about differences 
between CD and UC regarding how remission or disease activity affects the disease during 
pregnancy. In addition, some women decide to stop therapy prior to becoming pregnant. This 
further makes it difficult to determine if disease activity changes during pregnancy because of 
pregnancy alone or because of change, or discontinuation, of medications.  
 
Regardless of disease activity during pregnancy, there is little information about the course of 
disease activity post-partum. Of 105 women with CD who completed a questionnaire regarding 
disease postpartum, 66.1% reported adherence to medical therapy, noting quiescent disease and 
fear of transmission of medication to breast milk as reasons for non-compliance [26]. In the 
postpartum period, 15 (14.3%) of the women reported relapse in CD, though five of these 
women reported non-adherence to medications; six reported mild disease activity and nine 
women reported moderate activity [26].  
 
What is the effect of pregnancy on the microbiome? 
While differences in the microbiome have been observed in patients with IBD compared to those 
without IBD, the exact role of the microbiome in the pathogenesis of IBD disease remains 
unclear. The gut microbiome is affected by many factors, including the immune system, 
environment, diet and genetics [27, 28].  
 
There are limited data regarding the role of the microbiome and changes in the microbiome 
during pregnancy. One study including 91 pregnant women showed significant changes in the 
gut microbiota over the course of pregnancy [29]. Specifically, Koren et. al. observed an overall 
increase in Proteobacteria and Actinobacteria from the first to third trimester, a decrease in 
Faecalibacterium, and a decrease in the diversity of the microbiota [29]. Changes in diversity 
over this time period were not related to the health of the pregnant woman. During pregnancy, a 
woman’s immune system must adapt to avoid rejection of the fetus. At this time, the relationship 
between the observed changes in the microbiome and the immune system and the role of the 
bacteria are not known [30].  It has been hypothesized that the changes in microbiome may 
promote weight gain or may stimulate the innate immune response, the latter of which may affect 
disease course during pregnancy [30]. In addition, the impairment of innate immunity that has 
previously been reported in IBD may improve during pregnancy with changes in the microbiome 
and hormones that affect this immune response [30]. The mechanism by which disease 
inflammation may be increased or decreased during pregnancy is not entirely understood.  In 
pregnancy, the T helper 2 cell (Th2) responses are increased. CD is typically characterized by an 
exaggerated CD4 T helper 1 (Th1) cell response. The increased Th2 response in pregnancy may 
affect the Th1 response that is up-regulated in CD, resulting in decreased risk of flare [30].  
 
As noted, changes in the microbiome have been observed over the course of three trimesters 
during pregnancy. However, very little change has been observed during the perinatal period. A 
small study evaluating the composition of the gut microbiota of 7 patients from 3-7 weeks 
prepartum to up to 30 days postpartum showed no significant changes in the gut microbiome 
composition nor in fecal short chain fatty acids, glucose, lactate or calprotectin [31]. Additional 
studies are warranted to further characterize changes over a longer time period including the first 
and second trimesters and also to correlate changes in the microbiome with disease activity.  
 
Knowledge gaps: 
There are no studies on changes in the microbiome in patients with IBD during pregnancy and 
there are very limited data on the microbiome and pregnancy in general. Further investigation is 
warranted to better understand the changes that occur in the microbiome during a normal 
pregnancy and how these changes may affect, or be impacted by, disease activity and severity. 
At this time, it is unknown if changes in the microbiome can predict flare or remission, how 
pregnancy may affect the microbiome, and how changes in the microbiome affect birth 
outcomes.  
 
How do we know if a pregnant woman is flaring? 
Assessment of flares and disease activity during pregnancy can be challenging. Current measures 
to evaluate disease activity of IBD include serum inflammatory markers, fecal calprotectin, 
colonoscopy, radiographic imaging and clinical indices including the Harvey-Bradshaw Index 
(HBI), Simple Clinical Colitis Activity Index (SCCAI) and the short or long form Inflammatory 
Bowel Disease Questionnaire (IBDQ) (Table 1). However, evaluating disease activity during 
pregnancy is very difficult, as the available methods are either not validated during pregnancy or 
often avoided due to possible risk to the fetus.  During pregnancy, imaging studies and 
endoscopy are often avoided because of the risk of radiation to the fetus, possible toxicity of IV 
gadolinium (MRI contrast dye), and potential risks to the fetus from both an endoscopic 
procedure and administration of sedation. Inflammatory markers that are used to monitor disease 
activity in a non-pregnant patient increase during normal pregnancies in women without IBD. 
Disease activity questionnaires that have been validated in IBD, such as the Harvey-Bradshaw 
Index for CD, include questions both about the presence of an abdominal mass, which is difficult 
to assess during pregnancy, and bowel habits, which may change because of pregnancy and not 
because of a change in disease activity.  
 
Fecal calprotectin, a biomarker that recently has been studied to assess disease activity in non-
pregnant IBD patients, is a validated marker of disease activity in non-pregnant IBD patients, but 
there are insufficient data of its role during pregnancy. Fecal calprotectin correlates with 
inflammation of the colon and increases with disease activity and flares [32, 33]. A recent study 
has also shown that fecal calprotectin levels correlate with ileal inflammation seen on MR 
enterography and with surgical inflammation [34]. However, a small study showed no 
statistically significant difference in fecal calprotectin levels among patients with and without 
endoscopic evidence of recurrence or remission of CD one year after ileocecal resection [35]. 
The impact of pregnancy on levels of fecal calprotectin is not known. One small study that 
followed seven pregnant women without IBD reported a mean fecal calprotectin of 18.8 ±6.1 µg 
g
-1
 feces using ELISA and no change in fecal calprotectin levels from stool collected at four time 
points between week 34 of gestation to 30 days postpartum [31].  
 
Worsening of disease during pregnancy can have negative outcomes on the fetus, as fetal growth 
and development depend on the mother’s ability to provide nutrition [36]. Medical treatment 
should not be withheld when disease activity increases; however, medications that are used to 
treat IBD affect the immune system. While most are safe to give during pregnancy, 
administration of immune-modulating medications should only be given when essential, 
stressing the importance of the availability of reliable biomarkers and accurate means to assess 
disease severity during pregnancy in order to avoid administration of immune-modulating 
medications that may not be necessary during pregnancy. Currently available methods, including 
serum inflammatory markers, hematocrit, physical examination, Harvey-Bradshaw Index or 
Simple Clinical Colitis Activity Index and a patient’s overall well being can be utilized by the 
treating physician to assess whether a patient is having a flare. MRI without contrast is safe 
during pregnancy, and can be ordered if there is uncertainty regarding disease status. Flexible 
sigmoidoscopy without sedation may also be pursued if results would change management. As 
with non-pregnant patients, a trial of enemas or suppositories may be appropriate if a patient has 
distal disease, and medications, including immunomodulators and anti-TNF medications, may be 
prescribed if necessary.  
 
Knowledge gaps: 
The currently available methods/modalities of measuring disease severity during pregnancy are 
suboptimal. Imaging options are limited due to physicians’ and patients’ worry regarding 
radiation to the fetus, serum inflammatory markers increase due to pregnancy alone and 
endoscopy is not preferred due to the possible risks of sedation for the fetus. 
 
What medical treatment options are available for pregnant women with IBD? 
There have been multiple studies regarding the safety of medications used to treat IBD and their 
use during pregnancy and there are currently ongoing studies evaluating the safety of 
medications during pregnancy and while breast-feeding. Since women with flares of disease are 
at increased risk for premature birth, medical management of IBD throughout pregnancy is 
extremely important to prevent flares or treat worsening of disease when it presents. 
 
Despite recommendations to continue therapy and the safety of medications, studies have also 
shown that there is decreased adherence to medical therapy prior to and during pregnancy. 
Julsgaard et. al. showed that adherence to medical treatment among pregnant women with IBD 
was 60-75%.[37]. One predictor of non-adherence included fear of harming the fetus or 
negatively affecting fertility [37]. Medications that are commonly prescribed to patients with 
IBD, and that women often worry about continuing during pregnancy, include the biologic 
medications and also azathioprine/6-mercaptopurine. These two classes of medications will be 
reviewed.  
 
Biologics: 
Biologics are commonly prescribed medications for women with moderate to severe CD or UC , 
and recent data have shown that it is safe to administer these medications throughout pregnancy. 
Aside from small case reports, all studies regarding the use of anti-TNF medication during 
pregnancy reported in the IBD literature are detailed in Table 2. Although anti-TNF medications 
are considered to be safe during pregnancy, thalidomide, which has some anti-TNF effects, is 
pregnancy category X and should not be administered during pregnancy [38]. Teratogenic effects 
of thalidomide include defects in limb development and abnormalities in the cardiovascular, 
respiratory, gastrointestinal, genitourinary and central nervous systems. It is possible that initial 
hesitation to prescribe biologic therapy, including infliximab, adalimumab and certolizumab, 
derived from knowledge of the teratogenic effects of thalidomide and possible relation to effects 
of anti-TNF properties during pregnancy. However, data from the PIANO registry, a prospective 
study of the effects of medications during pregnancy among women with IBD, has shown the 
biologic medications to be safe during pregnancy [39]. 
 The London Position Statement of the World Congress of Gastroenterology reported that 
infliximab, adalimumab and certolizumab were all considered low risk and could be continued 
during conception and at least the first two trimesters of pregnancy [40]. In a meta-analysis, no 
significant differences in unfavorable pregnancy outcomes, rates of abortion, preterm birth, low 
birth weight or congenital malformations were shown when comparing the pregnancies of 
women with IBD taking anti-TNF medications and those not taking anti-TNF medications [41] 
Similar results showing no significant differences in pregnancy and neonatal outcomes were seen 
in a case-control study following 124 pregnant women over 133 pregnancies on anti-TNF 
therapy, including infliximab, adalimumab or certolizumab [42]. Smaller studies of 34 children 
born to mothers on infliximab or adalimumab showed no congenital malformations other than 
one case of hip dysplasia in a child [43] and another study of 28 children born to mothers on 
anti-TNF therapy reported one case of polydactyly but the mother had been on methotrexate 
prior to conception [44].  
 
Previously, many clinicians discontinued biologic therapy prior to the third trimester. 
Discontinuation of anti-TNF medication prior to week 30 of pregnancy results in significantly 
lower levels of medication in cord blood, though levels are still detectable [44]. Both 
adalimumab and infliximab have been detected in cord blood, and certolizumab is detected only 
at very low levels [45].  The PIANO study, a prospective study of 1085 women with IBD on 
immunomodulators and/or biologic therapy, showed no increased risk of congenital anomalies, 
preterm birth, intrauterine growth retardation, cesarean section or neonatal intensive care unit 
stay on monotherapy or combination therapy. However, subgroup analysis did show increased 
rates of preterm birth, low birth weights and NICU stay in infants born to mothers with UC on 
combination therapy [39]. Despite recent data showing that these medications are likely safe 
during pregnancy, the recent statement released by the European Crohn’s and Colitis 
Organization (ECCO) recommends discontinuing anti-TNF medication around gestational week 
24-26 if possible, but that the decision to discontinue a medication should be determined 
individually based on maternal disease activity [8]. 
 
Vedolizumab:  
There is currently very little data on pregnancy outcomes among women prescribed 
vedolizumab. One observational study followed pregnant women exposed to vedolizumab. 
Twenty-four women were exposed to vedolizumab prior to pregnancy and 27 pregnancies were 
reported (2 in healthy volunteers and 25 in women with a diagnosis of IBD) [46]. Eleven of the 
pregnancies resulted in a live birth, though two were premature.  One congenital anomaly of 
agenesis of the corpus callosum in the child of a healthy volunteer was reported.  
 
6-MP/Azathioprine: 
There has not been shown to be increased risk of poor pregnancy outcomes in patients on 
immunosuppressant therapy. A meta-analysis showed increased risk of preterm birth to 
newborns of mothers taking thiopurines, but no increased risk of congenital anomalies or low 
birth weight [47]. The risk of preterm birth may have been affected by disease activity and the 
actual effect of thiopurines on preterm birth is not entirely clear. An analysis comparing use of 
thiopurines, anti-TNF with or without thiopurines, and no exposure to thiopurines showed that 
rate of pregnancy complications was lower in the thiopurine exposed group and that women 
taking thiopurines had a more favorable global pregnancy outcome, with global pregnancy 
outcomes determined by rates of spontaneous or elective abortion, pregnancies that ended before 
37 weeks, obstetric complications and newborn intensive care unit admission, low birth weight, 
congenital malformation or death [48]. However, a meta-analysis including 312 pregnant women 
with IBD who were taking thiopurines during pregnancy showed that women taking thiopurines 
had a 2.95 increased odds of congenital abnormalities in babies born to women taking 
thiopurines compared to women taking no medications for IBD (95% confidence interval 1.03-
8.43) [49]; types of congenital abnormalities observed in the thiopurine group included Trisomy 
21, congenital hyperplastic heart, bilateral cataract, cervical angioma, congenital cataract, 
occipital encephalocele, sternocleidomastoid muscle and unspecified malformations of the skin 
[49]. Of note, there was no difference in congenital malformations among children born to 
mothers on thiopurines alone and children born to women on other IBD medications [49]. 
Congenital malformations observed in children born to women not taking thiopurines included 
renal atrophy, congenital reflux nephropathy, partial syndactyly, Pierre Robin syndrome, 
complex cardiac malformation and omphalocele. No other differences in prematurity, low birth 
weight, spontaneous abortion or neonatal adverse outcomes, were seen [49]. One study raises 
concern over the use of thiopurine during pregnancy. Of thirty patients who were taking 
azathioprine or mercaptopurine, 60% of children were born with anemia [50]. This study showed 
that during pregnancy, median 6-thioguanine nucleotide (6-TGN) concentrations decreased while 
6-methylmercaptopurine (6-MMP) increased, without evidence of hepatotoxicitiy or 
myelotoxicity. Fetal and maternal 6-TGN levels correlated positively, raising the question of 
whether newborns of mothers on thiopurines should be monitored for anemia [50]. All infants, 
even those with anemia, had normal APGAR scores and no congenital abnormalities were noted, 
though one infant was born with pancytopenia [50]. Similarly, studies have shown that 
breastfeeding while taking thiopurines is generally safe. Christensen et. al. measured the levels of 
thiopurines in breast milk during 6 hours after administration of 6-MP or azathioprine. The 
highest concentrations of medication in breast milk were observed within 4 hours of medication 
administration; however, maximum exposures of the drug to the children was less than 1% of the 
dose of the drug administered to the mother [51]. A cohort of children born to mothers taking 
azathioprine during pregnancy showed no negative effects on the child’s development or 
increased rates of infection in children followed for an average of 3.8 years after delivery [52]. 
However, long-term follow-up of these children is not yet available.  
 
Knowledge gaps 
Biologic and combination immunomodulator and biologic medications used to treat IBD are 
relatively new. Thus, additional studies are warranted regarding the safety of biologics and 
combination therapies during pregnancy. Data show that there are no significant effects on 
childhood growth and development in the first few years of life, but long-term effects of these 
medications on offspring are unknown. In addition, long term effects of children born to fathers 
treated with these medications at the time of conception is also unknown.  
 
How do we manage women with stable disease during pregnancy?  
Women who remain in remission during their pregnancy should continue their current therapy. 
As previously reviewed, most medications are safe to continue throughout pregnancy without 
increased risk of adverse events during pregnancy or adverse effects to the fetus.  Additional 
considerations regarding management of the pregnant IBD patient include risk assessment for 
venous thromboembolism (VTE) and monitoring for gestational diabetes. Women with UC are at 
risk of VTE, especially if they flare during pregnancy [53]. In addition, because women with 
IBD are at increased risk for VTE, prophylactic low molecular weight heparin should be 
considered in any woman who is hospitalized or flaring, or if they have additional risk factors for 
VTE [8]. Physicians should also be aware that women with CD are at higher risk of antepartum 
hemorrhage [53].  
 
It has been shown that women with IBD are at increased risk for development of gestational 
diabetes, however subgroup analysis showed that only those women who received steroids 
during pregnancy were at increased risk [54]. There was no significant difference in risk of 
gestational diabetes between women with IBD who had not received steroids and controls [54]. 
The PIANO registry following over one thousand pregnant women with IBD has also shown an 
increased risk of gestational diabetes among women who received steroids during pregnancy 
[55].  
 
Knowledge gaps: It is unclear if women should remain on combination therapy or de-escalate 
during pregnancy if in remission. At this time, we recommend that gastroenterologists continue 
biologics in the third trimester if the patient is flaring. However, further research is warranted to 
determine if biologic therapy can stopped during the third trimester if the patient is in remission. 
In addition, if medication is de-escalated during pregnancy, it is unclear if the therapeutic 
regimen used prior to pregnancy be re-started after delivery. 
 
How do we manage flares during pregnancy? 
As reviewed previously, administration of biologic and immunomodulator therapy is probably 
safe and these medications can be used to manage disease activity during pregnancy. 
Management of a flare during pregnancy is extremely important as the risk of preterm birth is 
increased in women with active disease. We know that disease severity is associated with worse 
pregnancy outcomes and therefore, aggressive therapy to control disease activity is 
recommended. Medications used to treat IBD in the non-pregnant patient have been shown to be 
safe during pregnancy and immunomodulators and anti-TNF medications should be prescribed if 
indicated. Medications that would be recommended in a non-pregnant patient should not be 
withheld from a pregnant patient if clinically indicated. A case-control study of pregnant IBD 
patients hospitalized with relapsing disease during pregnancy showed that women who had been 
hospitalized with a flare delivered three weeks earlier on average and had higher rates of pre-
term birth and lower birth weights [56]. However, there was no significant difference in APGAR 
scores of children born to mothers with and without flares, and no significant difference in the 
risk of complications [56].  
 
In general, endoscopic evaluation during pregnancy is not favored by patients or practitioners. 
However, if necessary, esophagogastroduodenoscopy, sigmoidoscopy and colonoscopy are 
considered to be safe during pregnancy, and the recent ECCO statement recommends performing 
these procedures only when strongly indicated and preferably in the second trimester if possible 
[8]. Sigmoidoscopy without sedation can be helpful in evaluating a patient with an UC flare. 
Obstetricians and anesthesiologists should assist in management of the IBD pregnant patient 
undergoing an endoscopic procedure and presence of fetal heart sounds should be confirmed 
prior to and after completion of the procedure [8].  Small studies have shown that EGD and 
colonoscopy are safe during pregnancy and are not associated with pre-term labor [57-59].  
 
There are little data on surgical outcomes during pregnancy, though case series of surgical 
intervention during pregnancy have been reported. In one study of three patients who underwent 
emergency colectomy within 2 days to 5 weeks postpartum, two of three infants died; one 
woman who had a colectomy twelve days antepartum also delivered a 1.4 kg newborn who 
survived [60]. All neonates were 33-40 weeks at the time of delivery. A second case series 
reported successful third trimester surgical intervention for fulminant colitis in two previously 
healthy women both diagnosed with IBD [61]. Both neonates survived although one was 
hospitalized for five weeks after birth for complications from respiratory distress syndrome.  
 
Imaging as a tool for assessing disease severity during pregnancy should be considered. Both 
MRI and CT may be possible during pregnancy. MRI without intravenous (IV) contrast is 
preferred over CT in pregnant patients (American College of Radiology ACR Appropriateness 
Criteria: Crohn Disease, 2014). MRI should not be performed with IV contrast as gadolinium 
crosses the placenta and long-term effects of exposure are not known. In addition, contrast is not 
required for adequate imaging during pregnancy. A case series of ten MR enterographies (MRE) 
were performed on nine patients without IV gadolinium and image quality was satisfactory [62]. 
In seven patients, imaging features consistent with CD were identified and penetrating 
complications of CD were visualized in four patients [62].  
 
Knowledge gaps:  
There are very few studies regarding the safety and role of surgical intervention during 
pregnancy. However, with early effective medical therapy, there should be little need for surgical 
intervention for fulminant disease.  
 
What is the recommended mode of delivery? 
Data show that rates of Cesarean section (C-section) are increased among women with IBD. 
Specifically, women with UC have an almost two-fold risk of elective C-section and women 
with active CD also have higher rates of elective C-section [53]. While there may be certain 
instances, such as active perianal disease, in which a C-section is recommended, vaginal 
deliveries are not contra-indicated in CD or UC. In a cohort of over 2000 patients, there was no 
difference in IBD-related surgery, hospitalization or escalation of medical therapy among women 
who had vaginal deliveries versus C-section [63].  Recommendations by the European Crohn’s 
and Colitis Foundation include C-section for active perianal disease or active involvement of 
disease [8]. The statement also notes that presence of an ileoanal pouch or ileorectal anastomosis 
is a relative indication for a C-section but that decision regarding mode of delivery in these 
instances should be made on an individual basis [8]. While it is recommended to discuss mode of 
delivery on a case-by-case basis, there is wide variation both within and between groups of 
colorectal surgeons, gastroenterologists and obstetricians regarding vaginal delivery after IPAA 
[64].  
 
Studies have shown no increased risk of development of a new perianal fistula after vaginal 
delivery compared to C-section among patients with CD [63], and thus vaginal delivery is not 
contra-indicated in CD. Women with UC have an almost double increased risk of elective C- 
sections [53]. However, it has been recommended that mode of delivery be determined on an 
individual case basis as a history of UC or a history of IPAA does not exclude the possibility of a 
vaginal delivery. History of IPAA does not in itself warrant delivery via C-section. A study 
following women with UC before and after delivery showed an increase in occasional nighttime 
incontinence among women who had a vaginal delivery, but no other difference in pouch 
function among women who had vaginal deliveries compared to those who had C-sections [65]. 
Other studies have shown similar results lacking significant change in pouch function after 
vaginal delivery [66].  A study of 49 deliveries among women with IBD and pouches showed no 
adverse effects on pouch function after vaginal delivery and no correlation between short-term 
functional impairment or complications of the pouch and mode of delivery [67]. A small study of 
twenty pregnant women with IPAA showed a statistically significant increase in frequency of 
nocturnal bowel movements during pregnancy and in the first three month after delivery, but this 
increase did not differ based on mode of delivery [68]. Juhazs et. al. showed that among 43 
women who became pregnant after undergoing IPAA, there was an increase in stool frequency, 
incontinence and pad use during pregnancy but that baseline pouch function was restored after 
pregnancy [69]. Pouch function was not compromised by vaginal delivery, multiple births, 
length of labor or birth weight and no permanent pouch function was observed among the 
women, who were followed for a mean of 2.4 years [69]. 
 
Knowledge gaps: 
Larger studies and longer follow up are necessary to determine long-term effects of mode of 
delivery on patients with IBD, especially those who have had prior IBD-related surgeries. At this 
time, mode of delivery is recommended on a case-by-case basis, and delivery via C-section is 
recommended in patients with active disease, in particular perianal disease. A discussion 
regarding C-section versus vaginal delivery can be had with the obstetrician and 
gastroenterologist in patients with an ileoanal pouch or anorectal anastomosis.  
 
Summary: The majority of patients with Crohn’s disease and ulcerative colitis are diagnosed 
between the ages of 15 and 30, which coincides with the peak years of fertility and pregnancy. 
Patients have many questions regarding fertility and pregnancy, especially those with increased 
disease activity, those taking immunosuppressive medications and those with a history of surgery 
for inflammatory bowel disease. We know that surgery for IBD can decrease fertility, and it 
would be very helpful for patients contemplating surgery to know whether in vitro fertilization is 
an option after surgery.  In addition, patients with increased disease activity and/or IBD surgery 
are often concerned about complications of a potential pregnancy.  One of our most common 
questions from both male and female patients is whether the IBD medications they are taking are 
safe for conception and pregnancy. While there are an increasing number of studies on the 
impact of IBD medications on pregnancy, there are fewer studies on the impact of disease 
activity, IBD surgery and long-term follow-up of children born by women with IBD. In addition, 
our ability to measure disease activity during pregnancy is impaired, as we still do not have a 
reproducible and standardized measure of bowel inflammation during pregnancy in the clinic or 
in the lab.  Prospective studies such as the PIANO study will help get us understand the affect of 
disease activity and immunosuppressive medications on pregnancy, birth and neonatal outcomes. 
However, studies on the effects of microbiome changes in pregnant IBD patients, the effects of 
combination immunomodulator + anti-TNF therapy versus monotherapy with anti-TNF, the 
course of disease activity post-partum, and, as mentioned above, assessing disease severity 
during pregnancy, are needed. There are even more gaps of knowledge in the field of fertility. 
While we are beginning to understand the efficacy of IVF in patients with IBD and the effect of 
laparoscopic surgery on fertility, we still do not know the effect of disease activity and IBD 
medications on fertility, the rate of ectopic pregnancies and the rate of pregnancy loss.  With the 
use of larger databases for pregnancy and fertility studies and large prospective studies in the 
near future, we will have meaningful information to enable our patients to make informed, 
evidence-based decisions.  
 
 
  
Table 1. Methods to Assess IBD Disease Activity During Pregnancy  
 
Method Benefit Potential Risk(s) Comments 
Colonoscopy -Gold standard for 
assessing disease 
activity in a patient 
with IBD 
-Medications used for 
sedation 
-Procedure may be 
technically difficult in 
a woman with a 
gravid uterus 
-Should preferentially 
be done in the 2
nd
 
trimester after 
discussion with GI, 
OB and anesthesia 
Flexible 
Sigmoidoscopy 
-Direct visualization 
and ability to take 
biopsies of the distal 
colon 
-May be done without 
sedation  
-May not be 
beneficial in patients 
who do not have 
rectal, sigmoid colon 
or descending colon 
involvement 
 
CT Enterography -Ability to visualize 
inflammation of the 
small and large 
intestine 
-Radiation risk to 
fetus 
 
MR Enterography -Satisfactory images 
to visualize 
radiographic changes 
consistent with 
Crohn’s flare 
-IV contrast used for 
MRIs is 
contraindicated during 
pregnancy  
-Optimal imaging 
protocol includes 
administration of 
gadolinium 
-MRI with gadolinium 
should not be 
performed during 
pregnancy due to risk 
of contrast to the fetus 
Fecal Calprotectin -May accurately 
reflect inflammation 
of the colon  
-There is currently 
insufficient data 
regarding the use of 
fecal calprotectin 
during pregnancy 
 
Sedimentation Rate -ESR is a nonspecific 
marker of 
inflammation and 
often increases with 
increase in disease 
severity  
-ESR is affected by 
pregnancy alone and 
may not be an 
accurate reflection of 
disease activity 
 
C-reactive protein -CRP is a nonspecific 
marker of 
inflammation and 
often increases with 
worsening of disease  
-CRP is affected by 
pregnancy and not 
only disease activity 
 
 
 
  
Table 2. The Safety of anti-TNF Medications During Pregnancy in Women with IBD 
 
Author Anti-TNF Publicati
on 
Year   
Number of 
pregnancies 
in exposed 
group 
Number of 
pregnancies 
in control 
group 
Control Congenital 
Anomalies in 
anti-TNF 
group 
Complications 
Katz et. al. 
[70] 
IFX 2004 83 135 Pregnant CD 
women not 
on anti-
TNF; 
Pregnant 
women in 
the general 
US 
population 
Tetralogy of 
Fallot 
Intestinal 
malrotation 
No increased risk in 
adverse pregnancy 
outcomes compared to 
controls 
Mahadevan 
et. al. [71] 
IFX 2005 10 n/a None None 3 pre-term, one low 
birth rate, no control 
group 
Schnitzler 
et. al. [72] 
IFX/ADA 2011 42 78 Pregnancies 
after IBD 
diagnosis 
but prior to 
anti-TNF 
treatment 
1 trisomy 18 No increased risk in 
pregnancy or neonatal 
complications 
compared to controls 
Zelnikova 
et. al. [73] 
IFX 2011 4 n/a None 1 polydactyly None 
Lichtenstein 
et. al. [74] 
IFX 2011 142 75 Pregnant 
women with 
CD not on 
anti-TNF 
Not reported 7.6% IFX, 14.7% 
controls, no specifics 
reported 
Mahadevan 
et. al. [39] 
IFX/ADA/ 
CTZ 
2012 458 356 (no 
AZA/6-
MP/anti-
TNF); 230 
(+ ADA/6-
MP/no anti-
TNF) 
 Not increased 
from controls; 
No specifics 
reported 
Increased rates of 
preterm birth, NICU 
stay, low birth rates for 
UC women on 
combination AZA/6-
MP + anti-TNF 
Arguelles-
Arias et. al. 
[75] 
IFX 2012 12 n/a None None No increased 
complications 
Casanova et. 
al. [48] 
IFX/ADA/ 
CTZ 
2013 66 318 Pregnant 
women with 
IBD not on 
thiopurines 
or anti-TNF 
Cardiac 
malformation 
No increased risk in 
pregnancy or neonatal 
complications 
compared to controls 
Zelnikova 
et. al. [44] 
IFX/ADA 2013 31 n/a None 1 polydactyly 3 miscarriages 
Mahadevan 
et. al. [45] 
IFX/ADA/ 
CTZ 
2013 31 n/a None None No serious 
complications 
Bortlick et. 
al. [43] 
IFX/ADA 2013 41 n/a None 1 hip dysplasia No serious 
complications 
Seirafi et. al. 
[42] 
IFX/ADA/ 
CTZ 
2014 133 99 Pregnant 
women with 
IBD not on 
anti-TNF 
1 missing finger No increased risk in 
pregnancy or neonatal 
complications 
compared to controls 
Diav-Citrin 
et. al. [76] 
IFX/ADA/ 
Etanercept 
2014 83 (41 IBD 
+42 
rhuematologic 
disease) 
86 
 
341 
+disease-
matched and 
no anti-
TNF. No 
autoimmune 
and no anti-
TNF 
1 VSD 
1 unilateral 
renal agenesis; 
1 Kaposiform 
hemangioendo-
thelioma; 
Kasabach-
Merritt 
syndrome; 
bilateral 
hydronephrosis 
No increased risk in 
pregnancy or neonatal 
complications 
compared to controls 
Weber-
Schoendorfe
r et. al. [77] 
IFX/ADA/ 
CTZ/ 
Golumumab/
Etanercept 
2015 495 (238 IBD 
+257 
rheumatologic 
disease) 
1532 Non anti-
TNF-
exposed 
pregnant 
women in 
the general 
population 
12.3% major + 
minor 
anomalies 
versus control 
group; 6.2% 
controls (OR 
1.64 (1.1, 2.6)) 
Increased preterm 
births, lower birth 
weight in anti-TNF 
group versus controls 
de Lima et. 
al. [78] 
IFX/ADA 2015 106 804 No anti-
TNF; No 
autoimmune 
disease 
Cleft palate; 
VSD, 
polydactyly 
Lower birth weight, 
more C-section, shorter 
gestational term than 
controls 
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